Evofem Biosciences, Inc.
$131.4K 4,790 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Agile Therapeutics, Inc.
Agile Therapeutics, Inc. reported $131,183.59 across General Payments, Research, and Ownership to 2,876 physicians and teaching hospitals across 2,876 transactions.
- $131.2K Below-median payer
- All-tracks total
- 2,876 Top quartile volume
- Transactions
- 2,876 Top quartile reach
- Recipients
- −$6.5K
- General Payments vs PY2023
Agile Therapeutics, Inc. reported $131,183.59 across all CMS Open Payments tracks (General + Research + Ownership) to 2,876 physicians and teaching hospitals in Program Year 2024 - ranking #1111 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $131,183.59, averaging $45.61 per recipient.
Agile Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
24/100
Total payments
F
11/100
Transaction volume
F
31/100
Physician reach
F
32/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer agile-therapeutics-inc Agile Therapeutics, Inc.
$131.2K · #1111/1,925 · 0.0% industry · PY2024
- TOT $131.2K
- RANK #1111
- SHARE 0.0%
- TXN 2,876
- RCP 2,876
- CAT 2
- GEN $131.2K
- ΔGEN −$6.5K
- TOP1 58.8%
- PY 2024
Volume peers
Nearest volume peer: Evofem Biosciences, Inc. ($131.4K)
Agile Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Agile Therapeutics, Inc.'s CMS-reported General Payments decreased by $6.5K (−4.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AGILE THERAPEUTICS, INC.PY2023: AGILE THERAPEUTICS, INC.PY2024: Agile Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $137,644.50
- PY2024
- $131,183.59
What the Data Shows for Agile Therapeutics, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Agile Therapeutics, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
1 transactions worth $77.2K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 58.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, Agile Therapeutics, Inc.'s largest category was "Consulting Fee" at $77.2K - 58.8% of General Payments.
How Agile Therapeutics, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $77.2K | 1 | 58.8% |
| Food and Beverage | $54.0K | 2,875 | 41.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $77,730.30 (59.3%) of $131,183.59 in this company's General Payments records across 2,027 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Agile Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
SANDRA Ann CARSON
$77,177.42 across 1 reported transactions
- 2
Yuliya O Boruch
$160.74 across 7 reported transactions
- 3
Katherine E Cornforth
$134.31 across 10 reported transactions
- 4
Ephraim M Ovitsh
$133.58 across 11 reported transactions
- 5
Tanya E Boatwright
$124.25 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Agile Therapeutics, Inc. ranks #1111 of 1,925 by total payments (bottom 42% by spend) but is notably more concentrated than that alone would suggest -- #508 of 1,838 by HHI (top 28% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- J. Morita USA, Inc. : $88.2K total payments, HHI 3500
- DTE Oregon, Inc. : $304.57 total payments, HHI 3497
- Alcon Research LLC : $7.1M total payments, HHI 3482
- Winter Innovations, Inc. : $4.7K total payments, HHI 3468
- ONY Biotech Inc. : $39.6K total payments, HHI 3464
- Cardinal Health 110 LLC : $92.3K total payments, HHI 3463
- Agile Therapeutics, Inc. (this company) : $131.2K total payments, HHI 3462
- Novabone Products : $19.0K total payments, HHI 3461
- NovoSource, LLC : $22.9K total payments, HHI 3460
- Datascope Corp. : $1.6M total payments, HHI 3460
- Bristol Myers Squibb Company : $1.0M total payments, HHI 3447
- Collegium Pharmaceutical, Inc. : $1.5M total payments, HHI 3442
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Agile Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Agile Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Agile Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Kamada Ltd.
$131.8K 129 recipients
Compare payment profiles
Actuated Medical, Inc.
$131.9K 5 recipients
Compare payment profiles
Elucid Bioimaging Inc
$130.1K 6 recipients
Compare payment profiles
Geron Corporation
$129.2K 442 recipients
Compare payment profiles
Dentsply Sirona Orthodontics Inc
$133.4K 103 recipients
Compare payment profiles
Put this to use
Agile Therapeutics, Inc. ranks #1111 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Agile Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.